Salvage Treatment of Relapsed/refractory LCH

Overview

Journal Blood Res

Publisher Springer Nature

Specialty Hematology

Date 2017 Jan 17

PMID 28090481

Citations 1

Authors

Jong Jin Seo

Affiliations

Soon will be listed here.

Citing Articles

Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature.

Silva K, Magalhaes I, Benincasa D, Cecconello D, Michalowski M Cancer Rep (Hoboken). 2024; 7(8):e2142.

PMID: 39190425 PMC: 11348861. DOI: 10.1002/cnr2.2142.

References

Allen C, Ladisch S, McClain K . How I treat Langerhans cell histiocytosis. Blood. 2015; 126(1):26-35. PMC: 4492195. DOI: 10.1182/blood-2014-12-569301. View

Donadieu J, Bernard F, Van Noesel M, Barkaoui M, Bardet O, Mura R . Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015; 126(12):1415-23. PMC: 4624454. DOI: 10.1182/blood-2015-03-635151. View

Arico M . Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy. Br J Haematol. 2016; 173(5):663-70. DOI: 10.1111/bjh.13955. View

Uppuluri R, Ramachandrakurup S, Subburaj D, Bakane A, Raj R . Excellent remission rates with limited toxicity in relapsed/refractory Langerhans cell histiocytosis with pulse dexamethasone and lenalidomide in children. Pediatr Blood Cancer. 2016; 64(1):110-112. DOI: 10.1002/pbc.26199. View

Veys P, Nanduri V, Baker K, He W, Bandini G, Biondi A . Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. Br J Haematol. 2015; 169(5):711-8. PMC: 4433436. DOI: 10.1111/bjh.13347. View

Simko S, Tran H, Jones J, Bilgi M, Beaupin L, Coulter D . Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2013; 61(3):479-87. PMC: 4474604. DOI: 10.1002/pbc.24772. View

Rigaud C, Barkaoui M, Thomas C, Bertrand Y, Lambilliotte A, Miron J . Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol. 2016; 174(6):887-98. DOI: 10.1111/bjh.14140. View

Haroche J, Cohen-Aubart F, Emile J, Arnaud L, Maksud P, Charlotte F . Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2012; 121(9):1495-500. DOI: 10.1182/blood-2012-07-446286. View

Heritier S, Emile J, Barkaoui M, Thomas C, Fraitag S, Boudjemaa S . BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. J Clin Oncol. 2016; 34(25):3023-30. PMC: 5321082. DOI: 10.1200/JCO.2015.65.9508. View

10.

Monsereenusorn C, Rodriguez-Galindo C . Clinical Characteristics and Treatment of Langerhans Cell Histiocytosis. Hematol Oncol Clin North Am. 2015; 29(5):853-73. DOI: 10.1016/j.hoc.2015.06.005. View